Organization | Children's Hospital of Philadelphia

Children's Hospital of Philadelphia Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4

Organization Overview

First Clinical Trial

2006

NCT00572975

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Erik Allen Jensen | Kristin Fiorino | Robert Schultz | Stephan Grupp MD PhD | The Children's Hospital of Philadelphia

Active Ingredients

Drugs in Phase 4 Trials (2)

pentadecanoic acid (1 trial)

triheptadecanoin (1 trial)

Drugs in Phase 2 Trials (2)

cd3,cd19 depleted hematopoietic stem cells (1 trial)

oxytocin (syntocinon) (1 trial)

Drugs in Phase 1 Trials (5)

ceritinib (zykadia) (1 trial)

ribociclib (kisqali) (1 trial)

siremadlin (1 trial)

tobramycin (nebcin) (1 trial)

trametinib (mekinist) (1 trial)

Drugs in Other Trials (2)

desflurane (suprane) (1 trial)

domperidone (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Autism Spectrum Disorder (Phase 2)

Autistic Disorder (Phase 2)

Bronchopulmonary Dysplasia (Phase 1)

Neuroblastoma (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 7
# of Trial APIs: 11